Award Type [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] Accounts payable ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Receivable [Member] Accounts receivable, net Accounts Receivable [Abstract] Accrued distribution fees Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued incentives Accrued payroll and other compensation Accrued Expenses and Other Current Liabilities [Abstract] Accrued Liabilities and Other Liabilities [Abstract] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional paid-in capital Additional Paid in Capital Additional Paid-in Capital [Member] Warrants issued in connection with note payable Adjustments to Additional Paid in Capital, Warrant Issued Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Amortization of intangible assets Amortization of intangible assets Amortization of debt discount Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Impairment of Long-lived Assets [Abstract] Construction in Process [Member] ASSETS Assets [Abstract] TOTAL ASSETS Total assets Total current assets Assets, Current Current assets: Base Rate [Member] Basis of Presentation Buildings and Building Improvements [Member] Building [Member] Cash and cash equivalents Cash and cash equivalents - beginning of year Cash and cash equivalents - end of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash balance Cash and cash equivalents Cash Equivalents, at Carrying Value SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Warrant to purchase shares of common stock (in shares) Class of Warrant or Right [Line Items] Class of Warrant or Right [Table] Warrant exercise price per share (in dollars per share) Warrants outstanding (in shares) Warrants outstanding (in shares) COMMITMENTS AND CONTINGENCIES [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Common Stock [Member] Common stock, available for issuance (in shares) Common stock, par value (in dollars per share) Common stock, par value (in dollars per share) Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 222,262,588 and 221,816,930 shares issued and outstanding Common stock, shares issued (in shares) Common Stock [Abstract] Common stock, shares authorized (in shares) Common stock, shares authorized (in shares) Common stock, shares outstanding (in shares) Common stock, shares outstanding (in shares) Concentration Risk Type [Axis] Concentration Risk [Line Items] Concentration Risk Type [Domain] Concentration Risk Benchmark [Domain] Concentration risk, percentage Percentage of consolidated revenues Percentage of account receivables Schedule of Product Information [Table] Concentration Risk Benchmark [Axis] Current portion of deferred revenue Corporate [Member] Corporate Segment [Member] Cost of Product Revenue Cost of product revenue Cost of product revenue Cost of Revenue Cost of Product Revenue [Member] OPERATING EXPENSES: Customer Concentration Risk [Member] Debt Instrument, Redemption, Period [Axis] Increase applicable margin Percentage of prepaid principal amount Debt Instrument, Redemption, Period [Domain] Credit agreement, interest rate provided DEBT [Abstract] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Line Items] Debt Instrument [Line Items] Effective interest rate Debt Instruments [Abstract] Scheduled principal payments Less: Debt discount Debt Instrument, Unamortized Discount Redemption premium Debt Instrument, Unamortized Premium Debt Instrument, Name [Domain] Maturity date Deferred revenue, net of current portion Depreciation and amortization Depreciation and amortization expense Depreciation expense Depreciation, Depletion and Amortization Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Loss Per Common Share [Abstract] BASIC LOSS PER COMMON SHARE (in dollars per share) DILUTED LOSS PER COMMON SHARE (in dollars per share) Stock Options [Member] Unrecognized compensation expense, non option Unrecognized compensation expense recognition period Unrecognized compensation expense, stock options STOCKHOLDERS' EQUITY [Abstract] Equity Component [Domain] Fair value of warrants Fair Value of Financial Instruments Federal Funds Rate [Member] Payments on finance lease obligations Finance Lease, Principal Payments Remainder of 2023 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] 2024 Finite Lived Intangible Assets By Major Class Axis Finite-Lived Intangible Assets [Line Items] Accumulated amortization Estimated Aggregate Amortization Expense [Abstract] Cost Net Furniture and Fixtures [Member] Loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Loss on extinguishment of debt Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Impairment charges related to goodwill Goodwill, Impairment Loss Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill Goodwill Goodwill [Abstract] Goodwill, Impaired, Accumulated Impairment Loss [Abstract] INTANGIBLE ASSETS [Abstract] Gross profit Gross Profit Impairment of long-lived assets Impairment, Long-Lived Asset, Held-for-Use Impairment of Long-Lived Assets Income Statement Location [Axis] Income Taxes [Abstract] Income Statement Location [Domain] CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Income Taxes Accounts receivable Increase (Decrease) in Accounts Receivable Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Inventories Increase (Decrease) in Inventories Changes in operating assets and liabilities: Other current and non-current liabilities Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Stockholders' Equity [Roll Forward] INTANGIBLE ASSETS Intangible assets, net Interest expense Interest Expense Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities INVENTORIES [Abstract] Finished goods INVENTORIES Inventories Inventory, Policy [Policy Text Block] Inventories Total inventories Inventory, Net Raw materials Work-in-process Interest income LEASE OBLIGATIONS Remainder of 2023 2028 Thereafter 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two 2027 Year ended December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Year One 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Payments Under Lease Obligations Total payments Lessee, Operating Lease, Liability, to be Paid Land [Member] Leasehold Improvements [Member] LEASE OBLIGATIONS [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity TOTAL LIABILITIES Liabilities Total current liabilities Liabilities, Current Current liabilities: Lender Name [Axis] Line of Credit Facility, Lender [Domain] DEBT Contingencies [Line Items] Contingencies [Table] Manufacturing and Laboratory Equipment [Member] CASH FLOWS FROM FINANCING ACTIVITIES: Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities CASH FLOWS FROM INVESTING ACTIVITIES: CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Net loss NET LOSS Net income (loss) International [Member] Noncash Financing and Investing Activities [Abstract] Other expense, net Nonoperating Income (Expense) OTHER INCOME (EXPENSE): Senior Notes Payable [Abstract] Office Equipment and Computer Software [Member] Weighted average remaining term Lease obligations, net of current portion Balance at March 31, 2023 Current portion of lease obligations Current portion Payments Under Lease Obligations [Abstract] Right-to-use assets Cash payments for lease Operating Lease, Payments Aggregate lease expense Operating Lease, Expense LOSS FROM OPERATIONS Income (loss) from operations Operating Income (Loss) Plasma Center Operating Expenses [Member] Total operating expenses Operating Expenses Operating Segments [Member] ORGANIZATION AND BUSINESS ORGANIZATION AND BUSINESS [Abstract] Plasma center operating expenses Other non-current liabilities Other expense Other Interest paid in kind Interest paid-in-kind ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract] Payment of deferred financing fees Payments of Financing Costs Payment for certain fees and expenses Payments of Debt Issuance Costs Purchase of property and equipment Capital expenditures Payments to Acquire Property, Plant, and Equipment Plan Name [Domain] Plan Name [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Capital Shares Reserved for Future Issuance Preferred stock, shares issued (in shares) Preferred stock, par value (in dollars per share) Preferred stock, par value (in dollars per share) Preferred stock, shares authorized (in shares) Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding Preferred stock, shares outstanding (in shares) Preferred stock, outstanding (in shares) Preferred Stock [Abstract] Prepaid expenses and other current assets Organization and Business [Abstract] Proceeds from Issuance or Sale of Equity [Abstract] Proceeds from issuance of note payable Estimated useful life Property, Plant and Equipment, Useful Life PROPERTY AND EQUIPMENT Property, Plant and Equipment [Line Items] Property and Equipment Property, Plant and Equipment [Table Text Block] Property Plant And Equipment By Type Axis PROPERTY AND EQUIPMENT [Abstract] Total property, plant and equipment, net Property and equipment, net Property, plant and equipment, gross Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment [Abstract] Accounts Receivable Receivable [Policy Text Block] RELATED PARTY TRANSACTIONS [Abstract] Related Party Transaction [Line Items] Purchased materials amount Related Party Transaction, Purchases from Related Party Related Party Transactions [Abstract] Related Party Transaction, Due from (to) Related Party [Abstract] Rent expense RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Related Party [Domain] Related Party [Axis] Principal payments on notes payable Payment for outstanding obligations Repayments of Notes Payable Research and Development Expense Research and development Research and Development [Member] Restricted Stock Units [Member] RSUs [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated Deficit [Member] Revenues Revenues Revenue from Contract with Customer, Excluding Assessed Tax Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenues [Member] Revenue from Contract with Customer, Product and Service Benchmark [Member] Revenue from Contract with Customer Benchmark [Member] Net Revenues According to Geographic Area Revenue Recognition [Abstract] Revenue Recognition Weighted average remaining contractual life of stock options, expected to vest Expected term Expected term Weighted average remaining contractual life of stock options, exercisable Weighted average remaining contractual life of stock options, outstanding Intangible Asset Future Aggregate Amortization Expense Revenue Benchmark [Member] Schedule of Unvested RSU Activity Schedule of Assumptions Schedule of Option Activity Schedule of Stock-Based Compensation Expense Schedule of Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Components of Inventory Summary of Outstanding Senior Notes Payable Schedule of Finite-Lived Intangible Assets [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Calculation of Diluted Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Accrued Expenses and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Supplemental Cash Flow Information Schedule of Related Party Transactions, by Related Party [Table] Property, Plant and Equipment [Table] Schedule of Segment Reporting Information, by Segment [Table] Summarized Financial Information Concerning Reportable Segments Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Secured Overnight Financing Rate [Member] SEGMENTS Segment Reporting Information [Line Items] Segments [Domain] Segment Reporting Information [Abstract] SEGMENTS [Abstract] Selling, General and Administrative [Member] Selling, general and administrative Senior notes payable, net of discount Senior notes payable Forfeited, Weighted average grant date fair value (in dollars per share) Equity incentive plans, vesting period Restricted stock units vested over a period Unvested RSU, Weighted Average Grant Date Fair Value Equity incentive plans, term Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Number of stock options granted (in shares) Number of restricted stock units granted (in shares) Unvested RSU, Shares [Abstract] Unvested, Weighted average grant date fair value, beginning balance (in dollars per share) Unvested, Weighted average grant date fair value, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Stock-based compensation Total stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Granted, Weighted average grant date fair value (in dollars per share) Stock-based Compensation [Abstract] Fair Value Assumptions and Methodology [Abstract] Vested, Weighted average grant date fair value (in dollars per share) Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Options exercisable, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Volatility Volatility Risk-free interest rate Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Dividend yield Dividend yield Options outstanding, vested and expected to vest, ending balance (in shares) Options outstanding, vested and expected to vest, beginning balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Stock Options, Vested and Expected to Vest [Abstract] Options outstanding, vested and expected to vest, weighted average exercise price, ending balance (in dollars per share) Options outstanding, vested and expected to vest, weighted average exercise price, beginning balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Award Type [Domain] Total stock-based compensation expense, Amount [Abstract] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Balance (in shares) Balance (in shares) Shares, Outstanding SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract] Segments [Axis] Equity Components [Axis] Statement [Line Items] CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] Statement [Table] CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY [Abstract] Exercise of stock options Exercise of stock options (in shares) Common stock shares issued (in shares) Balance TOTAL STOCKHOLDERS' EQUITY Balance Stockholders' Equity Attributable to Parent STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY Stockholders' Equity Attributable to Parent [Abstract] SUBSEQUENT EVENT Subsequent Event [Table] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Type [Axis] Subsequent Event [Line Items] SUBSEQUENT EVENT [Abstract] SUPPLEMENTAL CASH FLOW INFORMATION [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Uncertain tax positions Unrecognized tax benefits Use of Estimates Variable Rate [Domain] Variable Rate [Axis] Warrants [Member] Fair value of warrants Warrants and Rights Outstanding Diluted (in shares) Basic (in shares) WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Counterparty Name [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Directors [Member] Director [Member] Customer [Axis] Major Customers [Axis] Maximum [Member] Minimum [Member] Customer [Domain] Product and Service [Domain] Product and Service [Axis] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Counterparty Name [Domain] Forecast [Member] Scenario [Domain] Geographical [Domain] Geographical [Axis] Scenario [Axis] Title of Individual [Axis] Title of Individual [Domain] United States [Member] Cover [Abstract] Document Type Document Quarterly Report Document Transition Report Entity Interactive Data Current Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding The amount of difference between current assets and liabilities. Working Capital Working capital Number of plasma collection facilities having FDA license. Number of FDA-Licensed Plasma Collection Facilities Number of FDA-licensed plasma collection facilities Number of products approved by FDA. Number of FDA Approved Product Number of FDA approved product Number of plasma collection facilities under various stages of development. Number of Plasma Collection Facilities Under Development Number of plasma collection facilities under approval and development Present value of lessee's discounted obligation for lease payments from operating and finance leases. Operating and Financing Lease, Liability Operating and financing lease liabilities The cash outflow for payment of debt refinancing fees. Payment of debt refinancing fees Payment of debt refinancing fees Amount of noncash revenue related to amortization of license revenue. Amortization of License Revenue Amortization of license revenue Amount of cash outflow related to taxes on vested Restricted Stock Units. Taxes Paid on Vested Restricted Stock Units Taxes paid on vested Restricted Stock Units Amount of increase (decrease) in deposits and operating assets classified as other. Increase (Decrease) in Deposits and Other Assets Deposits and other assets Post-Marketing Commitments [Abstract] Vendor and Licensor Commitments [Abstract] Vendor and Licensor Commitments [Abstract] Plasma purchase agreement term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Plasma Purchase Agreement Term Plasma purchase agreement term Number of FDA inspections completed during the period. Number of FDA Inspections Percentage of plasma purchase price equal to cost purchased from collection centers. Percentage of Plasma Purchase Price Equal to Cost Percentage of plasma purchase price equal to cost Number of wholly-owned plasma collection facilities of the entity. Number of Plasma Collection Facilities Number of plasma collection facilities Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Plasma supply agreement term Plasma supply agreement term Number of renewal terms to extend purchase agreement, if agreed to by the parties. Number of Renewal Terms Number of renewal terms Percentage of inventory purchases related to raw material plasma. Percentage of Inventory Purchases Percentage of inventory purchases Amount of plasma purchased during the period. Plasma Purchased Plasma purchased from Grifols Number of plasma collection centers that company may purchase RSV plasma. Number of Plasma Collection Centers Transferred to Acquired Entity Number of plasma collection centers that collects RSV Plasma which were transferred to BPC Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Plasma Purchase Agreement Renewal Period Plasma purchase agreement renewal period Number of plasma collection facilities having FDA licenses approved. Number of FDA-Licensed Plasma Collection Facilities Approved Number of FDA-licensed plasma collection facilities approved Information about international customers accounting for a percentage of consolidated revenues. International Customers [Member] BIVIGAM an Intravenous Immune Globulin ("IVIG") product indicated for the treatment of Primary Humoral Immunodeficiency ("PI"), also known as Primary Immunodeficiency Disease ("PIDD"). BIVIGAM [Member] BIVIGAM [Member] Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. Plasma Purchase Agreement One [Member] 2011 Plasma Purchase Agreement [Member] Plasma purchase agreement to purchase normal source plasma ("NSP"). Plasma Purchase Agreement Two [Member] 2017 Plasma Purchase Agreement [Member] ASCENIV an Intravenous Immune Globulin ("IVIG") product indicated for the treatment of Primary Humoral Immunodeficiency ("PI"), also known as Primary Immunodeficiency Disease ("PIDD"). ASCENIV [Member] Value of stock related to Restricted Stock Awards issued during the period, net of shares withheld to cover grantees' income tax liability. Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, amount Vesting of Restricted Stock Units, net of shares withheld for taxes and retired Number of shares issued during the period related to Restricted Stock Awards, net of shares withheld to cover grantees' income tax liability. Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, shares Vesting of Restricted Stock Units, net of shares withheld for taxes and retired (in shares) Stock Options [Abstract] Stock Options, Weighted Average Exercise Price [Abstract] Weighted-average exercise price, for fully vested and expected to vest that were expired. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Weighted Average Exercise Price Expired, weighted average exercise price (in dollars per share) Stock Option, Shares [Abstract] Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Number Forfeited (in shares) Number of shares under fully vested and expected to vest options for which rights to exercise lapsed. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Number Expired (in shares) Number of shares under fully vested and expected to vest options that were exercised during the current period. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Number Exercised (in shares) Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Weighted Average Exercise Price Forfeited, weighted average exercise price (in dollars per share) Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Exercise Price Granted, weighted average exercise price (in dollars per share) A group of person working with the entity. Employees [Member] Employees [Member] Number of shares under fully vested and expected to vest options that were granted during the current period. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Number Granted (in shares) Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Weighted Average Exercise Price Exercised, weighted average exercise price (in dollars per share) Restricted Stock Units [Abstract] The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Value Withheld for Employees Tax Liabilities Amount of shares withheld for tax withholding obligation The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Withheld for Employees Tax Liabilities Shares withheld for tax withholding obligation (in shares) Represents 2022 compensation plan of equity based compensation arrangement plan. Two022 Compensation Plan [Member] 2022 Compensation Plan [Member] Equity compensation is often a significant portion of the total compensation paid to employees and other service providers. Equity Incentive Plans [Member] Equity Incentive Plans [Member] Principal balance of the loans and any other obligations advanced or otherwise owed. Long Term Liability, End of Term Fee Payable End of term fee Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other. Deposits and Other Noncurrent Assets Deposits and other assets Amount of warrants issued in connection with the issuance of notes payable. Warrants Issued in Connection with Notes Payable Warrants issued in connection with notes payable Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities. Equipment Acquired Reflected in Accounts Payable and Accrued Liabilities Equipment acquired reflected in accounts payable and accrued liabilities Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Amortization period Name of license agreement. Biotest License Agreement [Member] Number of major customers of the organization. Number of Customers Number of customers Number of customers Information about number of customers accounting for a percentage of consolidated revenues. Five Customers [Member] Information about number of customers accounting for a percentage of consolidated revenues. Two Customers [Member] Amount of allowance for contractual credits and doubtful accounts. Accounts Receivable, Allowance for Contractual Credits and Doubtful Accounts Accounts receivable, allowances for contractual credits and doubtful accounts Information about number of customers accounting for a percentage of consolidated revenues. Three Customers [Member] Number of remaining plasma collection facilities under construction during the period. Number of Remaining Plasma Collection Facilities Under Construction Number of remaining plasma collection facilities under construction Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment. ADMA BioManufacturing Segment [Member] ADMA BioManufacturing [Member] The amount of interest and other nonoperating income (expense). Interest and Other Nonoperating Income (Expense) Interest and other expense, net Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment. Plasma Collection Centers Segment [Member] Plasma Collection Centers [Member] A Hayfin credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender. Hayfin Credit Agreement [Member] Hayfin Credit Agreement [Member] Warrants [Abstract] Warrants [Abstract] Person with designation of chief scientific officer and chief medical officer. Chief Scientific Officer and Chief Medical Officer [Member] Dr. James Mond [Member] Name of the entity associated with related party. Areth, LLC [Member] Name of the Lender in credit facility agreement. Perceptive Credit Holdings II, LP [Member] Perceptive [Member] Name of the entity associated with related party. GenesisBPS [Member] Genesis [Member] Minimum percentage of common stock held by lender and administrative agent of credit facility. Minimum Percentage of Common Stock held by Lender Minimum percentage of common stock held by lender Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product. Accrued Rebates, Current Accrued rebates Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Testing, Current Accrued testing Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount. Hayfin Credit Facility [Member] Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount. Hayfin Closing Date Loan [Member] The interest amount to be pay in kind during the reporting period. Debt Instrument, Interest Amount to be Pay in Kind Percentage of interest amount to pay in kind The cash outflow for payment of an upfront fee paid in kind to consortium of lenders under the debt instrument. Debt Instrument, Upfront Fee, Paid in Kind Upfront fee paid in kind Number of business days for prior written notice to pay outstanding principal loans subject to payment conditions. Number of Business Days For Prior Written Notice to Prepay Outstanding Principal Number of business days prior written notice for prepay outstanding principal The trailing period for volume-weighted average price, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Trailing Period for Volume Weighted Average Price Trailing period for VWAP Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Debt Instrument, Term of Variable Rate Term of variable rate Percentage points added to the reference rate to compute the margin rate on the debt instrument. Debt Instrument Applicable Margin Applicable margin Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion. Senior Notes Payable Before Debt Discount Notes payable Number of shares issued upon exercise of warrants. Shares Issued Upon Exercise Of Warrants Shares issued upon exercise of warrants (in shares) Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount. Hayfin Delayed Draw Loan [Member] The percentage of exit fee on outstanding principal amount being paid. Percentage of Exit Fee of Outstanding Principal Amount being Paid Percentage of exit fee on outstanding principal amount being paid The first anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement. Prepaid after the First Anniversary [Member] Prepaid after the First Anniversary [Member] The second anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement. Prepaid after the Second Anniversary [Member] Prepaid after the Second Anniversary [Member] The percentage floor rate on debt instrument. Debt Instrument, Floor Interest Rate Percentage of floor interest rate The first anniversary representing most current period of debt redemption features under terms of the debt agreement. Prepaid on or Prior to First Anniversary [Member] Prepaid on or Prior to First Anniversary [Member] Subsequent Event Additional Information [Abstract] Subsequent Event [Abstract] The percentage of reduction to forego early prepayment fees. Percentage of Reduction Prepayment Fees Percentage of reduction to forego early prepayment fees Entity entered into second amendment "Hayfin Second Amendment" in a debt arrangement. Hayfin Second Amendment [Member] Hayfin Second Amendment [Member] Entity's established relationships with its customers through contracts. Right to Intermediates [Member] Rights to Intermediates [Member] Entity's established relationships with its customers through contracts. Trademark and Other Intangible Rights Related to Nabi-HB [Member] Trademark and Other Intangible Rights Related to Nabi-HB [Member]